Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen
about
Treating brain tumors with PDE4 inhibitorsThe utility of transposon mutagenesis for cancer studies in the era of genome editing.Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studiesEpigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progressionThe cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cellsNeonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout lifeIdentification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome.Remobilization of Tol2 transposons in Xenopus tropicalis.Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas.TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cellsDuration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA deliveryKnockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway.Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells.Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers.Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancersIdentification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation.Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.Strategies for short hairpin RNA delivery in cancer gene therapy.RUNX3 is multifunctional in carcinogenesis of multiple solid tumors.The RUNX family in breast cancer: relationships with estrogen signaling.Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development.Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases.Sleeping Beauty transposition: from biology to applications.A novel approach to identify driver genes involved in androgen-independent prostate cancer.Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer.A Comprehensive Guide to Sleeping Beauty-Based Somatic Transposon Mutagenesis in the Mouse.Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.Investigation of the molecular mechanisms underlying postoperative recurrence in prostate cancer by gene expression profiling.PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.Transcription Factor Trps1 Promotes Tubular Cell Proliferation after Ischemia-Reperfusion Injury through cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4D and AKT.Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.Genomic DNA Methylation-Derived Algorithm Enables Accurate Detection of Malignant Prostate Tissues.New Prognostic Markers: The Pathway from Research to Clinical Practice
P2860
Q24628917-9416CB3F-D457-49E6-B68A-EED5A2D6ABE9Q26781762-59161511-39A9-425F-8FFB-D2B3A59FA552Q27008537-089EB6A6-A880-4535-800B-E40C5310DDEDQ27323950-786666C8-03F6-4FDF-B283-CF4D59FC152EQ28269917-52D172C8-92D6-4338-9775-E60B7381CA47Q28307581-ED8E48B1-C423-4F63-91EE-CE3DBCE27BD2Q28567904-23F1EF2F-A0D0-4408-9E27-607FA67B01D9Q31043876-61408D4B-202C-4352-9EE2-E40E3E107174Q33526057-DB41947F-C9C0-4B0F-B80E-CA232AE1942FQ33820449-F1B100AD-5C2E-4840-AD54-CBC09609F1B5Q33882562-EF2BE609-AD01-4E70-9BE2-A163D325416DQ34183415-E6702554-42C0-454A-B3F2-015C9461BD74Q34292964-2E15060C-CCA9-451D-8D05-63838A6CCF86Q34399240-36CD6EA9-1EAF-44BF-9219-F44AD98194DEQ35571704-0484CA07-CB1C-43B8-95EC-43D77FD7E31BQ36214663-BD6F1077-AD8E-4CBA-BCF4-377201143EFFQ36269684-CF2270D3-B9D8-4104-B30E-971FC663D295Q36451030-0220DFB6-DB8F-419E-BB86-FFACBEDC3C53Q36762760-AA904621-9F07-46D0-A9DD-E9CBDCEB831AQ36886070-6F34B1CB-7771-47C7-8749-48F188DC6741Q37123841-2E9E2088-9350-40E2-8078-234ADA4B107FQ37407179-F1CCD536-052F-49D1-859E-8CCDA740746BQ37481246-B65ACE4B-269E-48DE-99EC-5BF63C263C19Q37598928-11E1851B-A680-4D47-A194-0BC6835B19F2Q37720402-D5FB9FCF-2A87-4F08-B490-6B5703F3FD20Q38050410-1C12AAA5-9D49-4E83-831B-12BDBBE743E8Q38088419-30C07297-EC0D-49FB-A352-5A6139AFC2CCQ38205932-1AA00E06-A3F5-48D6-9414-E0B2E3792FB7Q38970768-AE36772E-71D8-4618-B827-57C7EDB8CA6DQ38989441-CCB4D2EB-4240-441D-A206-4146D58CEB4BQ39341456-978E94E5-09FA-4010-A3B9-5BE9C4C6FE12Q39359743-F6592A39-74F9-447F-86C6-C8737091A786Q40841671-168F1B33-F263-47E3-BBFE-B7D07F4F76BFQ41980556-991DE08F-68C8-4370-B1E2-8E9928D7BB99Q49335670-C24F3086-361B-4DD6-80D8-8F4F64C21F45Q51188245-8BEA9F74-2535-4F96-BA10-BA19F0DE57AAQ51611606-75C6C2E0-CB82-49F0-BCEC-1967DB0C8BE5Q52621195-6A1EEC71-0A65-41BC-BB3C-D1CE7B2DBF38Q55317207-E8675DC1-9BA2-4B30-8FB4-CC833953A976Q57238952-0221341D-688E-4166-8708-8511167B0750
P2860
Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification of PDE4D as a p ...... sed somatic mutagenesis screen
@en
Identification of PDE4D as a p ...... ed somatic mutagenesis screen.
@nl
type
label
Identification of PDE4D as a p ...... sed somatic mutagenesis screen
@en
Identification of PDE4D as a p ...... ed somatic mutagenesis screen.
@nl
prefLabel
Identification of PDE4D as a p ...... sed somatic mutagenesis screen
@en
Identification of PDE4D as a p ...... ed somatic mutagenesis screen.
@nl
P2093
P2860
P1433
P1476
Identification of PDE4D as a p ...... sed somatic mutagenesis screen
@en
P2093
David A Largaespada
Eric P Rahrmann
Keiko Akagi
Lara S Collier
Laura E Green
Laura Roethe
Meghan E Doyal
Michelle Waknitz
Paul C Marker
Rita L Malinowski
P2860
P304
P356
10.1158/0008-5472.CAN-08-3901
P407
P577
2009-04-28T00:00:00Z